colorectal cancer
Conditions
Interventions
Gold Standard:Clinical outcome
Index test:Therapeutic 
prediction 
model 
of 
line 
bevacizumab 
combined 
with 
mFOLFOX6 
in 
Ras 
cancer 
patients 
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Adult patients, aged 18-75 years. 2) Colonoscopic biopsy confirmed colorectal adenocarcinoma. 3) Ras mutation. 4) Preoperative imaging diagnosis of colorectal cancer liver metastasis. 5) Unresectable liver metastases by multidisciplinary assessment. 6) The hemopoietic functions of heart, lung, liver, kidney and bone marrow meet the requirements of operation and anesthesia. 7) Physical strength score 0-1. 8) The expected survival was more than 3 months. 9) Sign informed consent.
Exclusion criteria
Exclusion criteria: 1) had a history of malignant colorectal tumor. 2) Recent diagnosis of other malignant tumors. 3) Patients who have participated in or are participating in other clinical trials within 4 weeks before enrollment. 4) Liver metastases can be initially resectable. 5) ASA grade >= IV and / or ECoG physical status score >= 2. 6) Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or severe basic diseases can not tolerate surgery. 7) Have a history of serious mental illness. 8) Pregnant or lactating women. 9) Patients with other clinical and laboratory conditions considered by some researchers should not participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;SEN, SPE, ACC, AUC of ROC, PPV, NPV; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival;overall survival; | — |
Countries
China
Contacts
Public ContactWentao Tang
Zhongshan Hospital, Fudan University
Outcome results
None listed